After a strange seven days, AstraZeneca’s Covid-19 vaccine is in Phase 3
As of yesterday, AstraZeneca has begun recruiting healthy volunteers for a 30,000-subject U.S. study of its vaccine for Covid-19. That was an expected milestone, but one that came after days of speculation that some sort of plot was afoot.
First, the Financial Times reported that the Trump administration was considering an emergency use authorization for AstraZeneca’s vaccine before any Phase 3 data were available. Then, last week, a trial investigator told the Palm Beach Post that the U.S. trial was on hold due to “political pressure,” claiming the FDA was looking into whether the study needed to be conducted at all.
With that as prologue, AstraZeneca’s otherwise staid, undramatic announcement comes as something of a relief to public health experts worried that the science of vaccine development might get derailed by politics in the U.S. This clearly occurred to AstraZeneca, which yesterday issued a separate press release titled “Company reiterates core values to ‘follow the science’ and ‘put patients first.’”
First, the Financial Times reported that the Trump administration was considering an emergency use authorization for AstraZeneca’s vaccine before any Phase 3 data were available. Then, last week, a trial investigator told the Palm Beach Post that the U.S. trial was on hold due to “political pressure,” claiming the FDA was looking into whether the study needed to be conducted at all.
With that as prologue, AstraZeneca’s otherwise staid, undramatic announcement comes as something of a relief to public health experts worried that the science of vaccine development might get derailed by politics in the U.S. This clearly occurred to AstraZeneca, which yesterday issued a separate press release titled “Company reiterates core values to ‘follow the science’ and ‘put patients first.’”
.png)
No hay comentarios:
Publicar un comentario